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Abstract
The development of resistance remains a major obstacle to
long-term disease control in cancer patients treated with targeted
therapies. In BRAF-mutant mouse models, we demonstrate that
although targeted inhibition of either BRAF or VEGF initially
suppresses the growth of BRAF-mutant tumors, combined inhibi-
tion of both pathways results in apoptosis, long-lasting tumor
responses, reduction in lung colonization, and delayed onset of
acquired resistance to the BRAF inhibitor PLX4720. As well as
inducing tumor vascular normalization and ameliorating hypoxia,
this approach induces remodeling of the extracellular matrix,
infiltration of macrophages with an M1-like phenotype, and reduc-
tion in cancer-associated fibroblasts. At the molecular level, this
therapeutic regimen results in a de novo transcriptional signature,
which sustains and explains the observed efficacy with regard to
cancer progression. Collectively, our findings offer new biological
rationales for the management of clinical resistance to BRAF
inhibitors based on the combination between BRAFV600E inhibitors
with anti-angiogenic regimens.
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Introduction
Activating mutations in the BRAF oncogene occur in approximately
7% of human malignancies, including 50–60% of melanomas and
5–8% of colorectal cancers (CRCs) (Davies et al, 2002). BRAF
mutations are associated with adverse clinical outcomes in mela-
noma, thyroid carcinoma, non-small-cell lung cancer, and CRC
(Cantwell-Dorris et al, 2011). The most frequent BRAF mutation
(V600E) (Halilovic & Solit, 2008) affects the kinase domain, leading
to constitutive activation of the protein. Oncogenic BRAF induces
downstream phosphorylation of MEK and ERK, which in turn
triggers cell autonomous proliferation even in the absence of
extracellular growth factors (Davies et al, 2002).
Specific inhibitors of BRAFV600E, including vemurafenib and
dabrafenib, have been approved for treating BRAF-mutant meta-
static melanomas (Bollag et al, 2010; Flaherty et al, 2012; Hauschild
et al, 2012). Although these drugs show remarkable clinical efficacy
and improve overall survival, almost all patients develop resistance
and subsequently relapse (Bollag et al, 2010; Flaherty et al, 2012).
A combination of BRAF and MEK inhibition further improves time
to progression and overall survival in patients with metastatic mela-
nomas when compared with single-agent BRAF inhibition (Paraiso
et al, 2010). It is likely that the limited efficacy of combinations
targeting a single oncogenic pathway is due to the plasticity and
ability of cancer cells to circumvent such a blockade.
Additional strategies must be exploited to increase the efficacy of
BRAFV600E inhibitors and circumvent or delay the onset of resis-
tance. Several studies on the effects of BRAFV600E inhibitors on the
cellular transcriptional landscape have envisaged new, attractive
preclinical combinations with molecules affecting specific processes,
including glucose metabolism (Parmenter et al, 2014), the immune
response (Hu-Lieskovan et al, 2014), and autophagy (Goodall et al,
2014), to improve the antitumor effects of BRAFV600E inhibitors.
In physiological angiogenesis, the effects of pro-angiogenic mole-
cules are counterbalanced by those of endogenous inhibitors.
During tumor angiogenesis, this balance is tipped in favor of new
vessel formation. However, the resulting vessels are highly abnor-
mal both structurally and functionally. This balance could be
restored by removing the excess of VEGF-A (VEGF) or by blocking
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VEGF signaling, which would induce pruning of abnormal vessels,
resulting in vascular normalization characterized by improved
perfusion and alleviation of hypoxia. Hence, strategies that favor
vascular normalization could improve the efficacy of cancer
therapies (Jain, 2014).
We and others have previously demonstrated that BRAFV600E
triggers an angiogenic response by modifying the expression profile
of angiogenic inducers (Durante et al, 2011; Bottos et al, 2012;
Sadow et al, 2014). Thus, enhanced angiogenesis and tumor–stroma
cross-talk may represent an additional therapeutic target in the
context of BRAFV600E-driven tumors. We reported that BRAFV600E
inhibition by the vemurafenib analog PLX4720 in xenografts did not
reduce the number of tumor capillaries but instead favored vascular
normalization (Bottos et al, 2012).
Based on this premise, we hypothesized that BRAF-targeted inhi-
bitors could cooperate with anti-angiogenic regimens in the treat-
ment of BRAF-mutant tumors. Specifically, in this work, we
investigated the combined effects of PLX4720 and bevacizumab, an
anti-VEGF humanized monoclonal antibody, in xenograft models of
melanoma and CRC. We report that this dual treatment induces a
new genetic program that regulates myeloid cell recruitment and
extracellular matrix remodeling and is more efficient than either
single agent for controlling tumor growth and the onset of resistance.
Results
Dual BRAFV600E and VEGF targeting provides a combinatorial
benefit against BRAFV600E mutants tumor growth in vivo
Cohorts of CD1-immunocompromised mice bearing A375
BRAFV600E-mutant melanoma xenografts were treated with
PLX4720, bevacizumab, or a combination of both (COMBO).
PLX4720 or bevacizumab alone caused a clear delay in tumor
growth, resulting in a 45% or 56% reduction in tumor volume,
respectively, compared with vehicle alone. However, neither single
treatment induced a regression of initial tumor size. Concurrent
administration of the two drugs at the same doses increased antitu-
mor activity, with 88% reduction in tumor volume compared to
vehicle and shrinking by 58% the initial tumor size (Fig 1A). Simi-
lar results were obtained by treating CRC COLO205 xenografts.
PLX4720, bevacizumab, and COMBO, respectively, inhibited of 61,
57, and 80% tumor growth (Fig 1B). These data indicate that beva-
cizumab improves the efficacy of the therapeutic inhibition of the
oncogenic driver BRAFV600E.
Then, we evaluated the effect of PLX4720, bevacizumab, and
COMBO on lung colonization of the MC-1 cell line, which is an highly
metastatic variant of A375 cells (Orso et al, 2016) (Fig 1C). Treat-
ments were started 12 weeks after i.v. cell injection and maintained
up to week 14. Lung staining by hematoxylin–eosin (HE) revealed
that only COMBO treatment significantly reduced lung nodules area
compared to controls (vehicle, 5.1  1.4%; COMBO, 0.6  0.1%).
To investigate the mechanism sustaining the observed tumor
shrinkage, we measured cellular proliferation and apoptosis in A375
tumors. The number of proliferating cells did not differ significantly
among the three treatment groups. Bevacizumab, PLX4720, and
COMBO decreased Ki67 staining by 69, 55, and 58%, respectively,
compared to controls (n = 4 tumors; Fig 1D). By contrast, only
COMBO treatment induced a significant increase in apoptosis
(22.4  3.3%, n = 3 tumors) compared with vehicle (5.7  1.2%,
n = 3 tumors) as revealed by TUNEL staining; Fig 1E) and by the
accumulation of caspase-cleaved cytokeratin 18 fragment
(Appendix Fig S1). These findings support that the antitumor activ-
ity observed with COMBO treatment depends on an apoptotic
program rather than modification of tumor cell cycle.
Dual BRAFV600E and VEGF targeting promotes vascular
normalization and improves tissue perfusion in
BRAFV600E xenografts
We analyzed the vascular effects of bevacizumab and PLX4720 on
A375 and COLO205 xenografts, by evaluating microvessel density
(MVD) and microvascular area (MVA). In A375 tumors, MVD was
reduced by 51% after bevacizumab treatment compared with the
control (capillaries/mm2: control, 87.9  3.5; bevacizumab,
42.7  2.1). PLX4720 alone or associated with bevacizumab slightly
reduced MVD (n = 5 tumors; Fig 2A). The treatment with PLX4720,
bevacizumab, or COMBO resulted in a similar reduction in MVA
compared with the control group (vehicle, 11398.3  497.0 lm2;
PLX4720, 7186.7  522.3 lm2; bevacizumab, 5472.4  423.5 lm2;
COMBO 6881.1  615.8 lm2) (n = 6 tumors; Fig 2A).
The analysis of MVD and MVA in COLO205 xenografts
(Appendix Fig S2A) showed a different effect, characterized by
increased values of MVD and MVA following PLX4720 treatment,
▸
Figure 1. Effect of the combination of PLX4720 and bevacizumab on the growth of A375, COLO205, and MC-1 cells harboring BRAFV600E transplanted in
athymic nude mice.
A Mice bearing established A375 were treated with vehicle (n = 7), PLX4720 (n = 5); bevacizumab (n = 7) or COMBO (n = 5). Tumor growth is expressed as %
change of the initial tumor. **P < 0.01, ***P < 0.001 versus vehicle (PLX4720 P = 0.0049; bevacizumab P = 0.0003; COMBO P = 4.86E-06), ŦP = 0.015
compared to PLX4720.
B Mice bearing established COLO205 were treated with vehicle (n = 7), PLX4720 (n = 8); bevacizumab (n = 7) or COMBO (n = 8). Tumor growth is expressed as %
change of the initial tumor. ***P < 0.001 versus vehicle (PLX4720 P = 2.75E-05; bevacizumab P = 2.96E-05; COMBO P = 2.13E-07), ŦP = 0.039 compared to PLX4720.
C Melanoma MC-1 cells (5 × 105) were injected into the tail vein of CD1 mice. Lung colonization was assayed by HE staining and calculating the number of nodules
and their total area normalized per the total area of the lungs. The mice analyzed were as follows: start point, n = 6; vehicle, n = 7; PLX4720, n = 6; bevacizumab,
n = 6; COMBO, n = 7. *P = 0.031 versus vehicle.
D Representative images of tumor cell proliferation determined by immunofluorescence Ki67 staining in A375 xenografts treated as indicated. Bar graphs indicate the
Ki67+ area/tumor area (n = 4 tumors). ***P < 0.001 versus vehicle (PLX4720 P = 2.83E-08; bevacizumab P = 4.25E-13; COMBO P = 6.16E-08).
E Representative images of tumor cell apoptosis determined by immunofluorescence staining with TUNEL in A375 xenografts treated as indicated. Bar graphs indicate
the TUNEL+ area/tumor area (n = 3 tumors). ***P = 2.07E-10 versus vehicle.
Data information: The scale bars represent 1 cm (A, B), 100 lm (D), and 50 lm (E). The results are given as the mean  SEM. Significance was assessed by one-way
ANOVA test followed by post hoc pairwise analysis test (A–E).
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confirming previous observations (Bottos et al, 2012). On the
contrary, bevacizumab and COMBO reduced both parameters in this
model.
Then, we analyzed the vessel lumen diameter in both models. In
A375 xenografts, the average vessel lumen diameter decreased from
52.7  3.6 lm in vehicle-treated tumors to 35.3  3.7 lm and
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Figure 2. Vascular response of A375 and COLO205 xenograft tumors to PLX4720 and bevacizumab.
A Representative images of vasculature stained by an anti-CD31 antibody in A375 xenografts treated as indicated. Bar graphs indicate quantitative microvessel density
(MVD) and microvessel area (MVA) analysis (n = 5 tumors). ***P < 0.001 versus vehicle (MVD: bevacizumab P = 5.94E-25; COMBO P = 1.84E-04) (MVA: PLX4720
P = 4.98E-09; bevacizumab P = 1.16E-19; COMBO P = 3.00E-08).
B Representative images of vessel lumen in A375 xenografts treated as indicated. Bar graphs indicate the quantitative analysis of lumen diameters in A375 and COLO205 xenografts
(n = 3 tumors). *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle (A375: PLX4720 P = 0.0078; COMBO P = 0.011) (COLO205: PLX4720 P = 2.01E-06; COMBO P = 1.33E-07).
C Representative images of perfusing fluorescent beads and their relationship with microvessels in A375 xenografts treated as indicated. Bar graphs indicate the % of
CD31+ vessels co-stained with fluorescent beads (n = 4 tumors). **P < 0.01 versus vehicle (PLX4720 P = 0.0031; COMBO P = 0.0033).
D Representative images of hypoxia marker pimonidazole in A375 xenografts treated as indicated. Bar graphs show the % of tumor hypoxic area in A375 and COLO205
xenografts (n = 5 tumors). **P < 0.01, ***P < 0.001 versus vehicle (A375: PLX4720 P = 6.94E-12; COMBO P = 3.34E-11) (COLO205: PLX4720 P = 0.0015; bevacizumab
P = 0.0004; COMBO P = 0.0003).
Data information: The scale bars represent 100 lm in (A, D) and 50 lm in (B, C). The results are given as the mean  SEM. Significance was assessed by one-way
ANOVA test followed by post hoc pairwise analysis test.
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33.6  4.8 lm upon treatment with PLX4720 and COMBO, respec-
tively (n = 3 tumors; Fig 2B). Similar results were observed in
COLO205 (vehicle, 50.3  3.2 lm; PLX4720, 35.5  2.3 lm;
COMBO, 33.6  1.8 lm). Bevacizumab did not modify the lumen
area compared with vehicle in both tumor types.
In spite of the cell line-specific differences (Bottos et al, 2012),
these data indicate that COMBO and PLX4720 influence vascular
morphology by reducing vessel lumen areas as compared to
bevacizumab and vehicle. This hypothesis was further investigated
in the A375 xenografts. The vessel lumen was resolved and catego-
rized into different groups (from < 100 lm2 to > 600 lm2).
PLX4720 alone or in combination with bevacizumab increased the
number of the smallest capillaries (surface < 100 lm2) and reduced
the number of larger vessels (surface > 500 lm2; Appendix Fig
S2B). None of the different therapeutic treatments modified the
number of vessels with surface areas from 100 to 500 lm2.
These data indicate that BRAF inhibition and VEGF removal have
distinct effects on vascular size and that the reduction in number of
tumor capillaries induced by VEGF withdrawal is counteracted by
BRAFV600E inhibition, which influences capillary shape.
Modification of the vascular area is a component of vascular
normalization upon treatment with anti-angiogenic compounds (Jain,
2014). A specific hallmark of this process is the improvement of vascu-
lar perfusion, which was studied by the i.v. delivery of orange fluores-
cent microspheres. PLX4720 or COMBO increased vascular perfusion
in A375 xenografts compared with treatment with vehicle or beva-
cizumab (Fig 2C). As expected, PLX4720 treatment restored tissue
oxygenation in this model (Fig 2D) as well in COLO205 xenografts in
agreement with our earlier report (Bottos et al, 2012). Interestingly,
this positive effect was maintained when bevacizumab was combined
with PLX4720. Since normalization process may include improvement
of pericyte coverage, we assessed the presence of pericytes surround-
ing capillaries using the specific NG2 marker. We observed that none
of the treatments modified pericyte coverage compared with untreated
tumors in A375 xenografts (Appendix Fig S2C).
Consistent with our previous study (Bottos et al, 2012), we con-
firmed that PLX4720-mediated BRAFV600E inhibition changed the
architecture and functionality of vessels and abrogated tumor
hypoxia. Although bevacizumab reduced blood perfusion, its associ-
ation with PLX4720 did not.
Furthermore, the lack of any evident combinatorial effects
between bevacizumab and PLX4720 on tumor vessels, and on the
amount of murine VEGF detected in the xenografts (not shown),
suggests that the enhanced antitumor activity observed with
COMBO is likely independent of angiogenesis.
Gene expression profiling highlights extracellular matrix
remodeling and immunomodulation after dual BRAFV600E and
VEGF inhibition
In A375 xenografts, the stromal microenvironment is contributed by
the mouse. Therefore, species-specific analysis of gene expression
can discriminate the effects of different therapeutic regimens on
tumor (human) and stroma (mouse) compartment. Human and
mouse microarrays were analyzed separately to determine the
dynamic changes within each compartment of the xenograft upon
treatment with PLX4720, bevacizumab, or COMBO. Of the 23,025
human genes that were above background, a supervised comparison
(one-way ANOVA with Benjamini–Hochberg (BJ) false discovery
rate (FDR) correction) among the four treatment arms revealed a set
of 68 differentially modulated genes (Appendix Fig S3A).
Sample clustering analysis based on these 68 genes highlighted
minor variations in bevacizumab-treated samples with respect to
vehicle and a strong and concordant transcriptional shift in
PLX4720- and COMBO-treated samples. A comparison between each
treatment arm and the vehicle group by LIMMA (Smyth, 2005)
defined a subset of 340 genes modulated by PLX4720 alone (145 up-
regulated and 195 down-regulated), 201 genes modulated by
COMBO (152 up-regulated and 49 down-regulated), and only four
genes modulated by bevacizumab alone (two up-regulated and two
down-regulated).
The Venn diagrams in Fig 3A illustrate the overlapping subsets
of modulated genes, and the volcano plots (Appendix Fig S3B) show
the changes in the log2-fold change and P-values for all genes in the
three separate comparisons with respect to vehicle. DAVID was used
to identify the biological functions enriched in the different treat-
ments in human A375 melanoma cells, considering up- and down-
regulated genes separately (significant P-value < 0.05 after BJ FDR
method; Appendix Fig S3C). Genes that were down-regulated in
PLX4720 or COMBO groups were highly enriched in gene sets
involved in “oxygen levels” and “response to hypoxia”. This result
is consistent with the observation that tumors are less hypoxic after
treatment with PLX4720 or COMBO. Genes that were up-regulated
in the PLX4720 and COMBO groups showed enrichment in the Gene
Ontology (GO) categories of “immune response”, “defense
responses”, and “inflammatory response”. Interestingly, in the GO
categories related to immune and inflammatory responses, we iden-
tified a cluster of cytokine and chemokine genes. Genes involved in
extracellular matrix (ECM) organization, extracellular structure
organization, biological adhesion, and cell adhesion were only
modulated by treatment with PLX4720 alone (Appendix Tables S1
and S2). Taken together, these analyses indicate highly but not
completely overlapping functional processes triggered by PLX4720
and COMBO in the human cell compartment of the tumor. This
model does not indicate a significant direct functional signature for
bevacizumab treatment on the human cell compartment.
To further characterize the effects of COMBO on the microenvi-
ronment of A375 xenografts, we performed mouse-specific gene
expression profiling. Of the 14,533 mouse genes that were above
background, ANOVA highlighted a larger number of stromal mouse
genes that were significantly altered in the four treatment arms
compared to the human arrays (n = 806, one-way ANOVA after BJ
FDR correction). In this case, sample cluster analysis highlighted
expression similarities between the vehicle and bevacizumab groups
and between the PLX4720 and COMBO groups, with PLX4720 and
COMBO inducing a substantially wider gene modulation
(Appendix Fig S4A). A subset of bevacizumab-modulated genes
related to angiogenesis (compared with vehicle, fold change thresh-
old | log2 FC | of 0.5) is reported and further validated by quantita-
tive PCR analysis (Appendix Fig S4B and C). Volcano plots show the
changes in the log2-fold change and P-values for all genes for the dif-
ferent treatments (Appendix Fig S4D), and Venn diagrams illustrate
the overlapping subsets of modulated genes (Fig 3B). Among the
805 genes modulated by PLX4720 identified by LIMMA analysis, 517
were down-regulated, and 288 were up-regulated. COMBO had a
reduced modulatory effect (414 genes; 214 suppressed and 200
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Figure 3. Transcriptional profiling in A375 xenografts in response to PLX4720, bevacizumab, and COMBO.
A Venn diagram showing the overlapping subsets of modulated human genes (fold change |log2| ≥ 1, P-value < 0.01) in the PLX4720, bevacizumab, and COMBO
treatments versus vehicle.
B Venn diagram showing the overlapping subsets of modulated murine genes (fold change |log2| ≥ 1, P-value < 0.01) in the PLX4720, bevacizumab, and COMBO
treatments versus vehicle.
C Summary of the functional categories of mouse genes significantly enriched in response to PLX4720 and COMBO. GO analyses were performed individually on down-
or up-regulated genes using DAVID tool (biological process). GO terms are ranked by P-value corrected by BH method, and the number of genes is indicated. For a
complete list of significantly enriched GO groups see Appendix Tables S3 and S4.
D GSEA enrichment plots for “Reactome Cytokine Signaling in Immune System” and “Reactome Innate Immune System” (upper panels) and “Reactome Extracellular
Matrix Organization” and “Reactome Collagen Formation” (lower panels) highlight significant enrichment of the pathways relative to the immune response and a
decreased expression of the pathways relative to extracellular matrix remodeling in COMBO-treated tumors as compared to the other treatments (vehicle, PLX4720,
bevacizumab).
E Heatmap representation of gene expression changes within the “Reactome Innate Immune System” (left panel) and “Reactome Extracellular Matrix Organization”
(right panel) gene set. Genes in heatmaps are shown in rows, and samples are shown in columns. Expression level is represented as a gradient from high (red) to low
(blue). V, P, B and C, respectively, indicate vehicle, PLX4720, bevacizumab, and COMBO.
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induced). GO analysis was performed on the three treatment arms
compared with vehicle using DAVID (P < 0.05 with BH FDR correc-
tion), considering up- and down-regulated genes separately. Among
the down-regulated genes, PLX4720 treatment mainly targeted genes
belonging to GO terms characterizing functions and processes of the
vasculature (“blood vessel development”, “vasculature develop-
ment”, “blood vessel morphogenesis”, “angiogenesis”; Fig 3C and
Appendix Tables S3 and S4) in accordance with the observed effect
on tumor vessel shape and functions (Fig 2). DAVID analysis of the
COMBO response revealed that the top enriched functions belonged
to the immune response (up-modulated genes), blood vessel, and
cell adhesion (down-modulated genes; Fig 3C). A comparison
between the lists of genes modulated in A375 xenografts by
PLX4720 or COMBO with respect to vehicle revealed a subset of
commonly modulated genes and sizeable subsets of genes specifi-
cally modulated by one of the two treatments only.
Gene set enrichment analysis (GSEA) was carried out on mouse
microarray data set to identify associated biological processes and
pathways related to COMBO treatment. By comparing COMBO
group with all the other groups, GSEA revealed an enrichment of
genes involved in immune response (“Reactome Cytokine Signaling
in Immune System” and “Reactome Innate Immune System”) and
down-modulation of genes associated with the ECM remodeling
(“Reactome Extracellular Matrix Organization” and “Reactome
Collagen Formation”; Fig 3D). This analysis was confirmed by the
heatmaps of genes associated with these categories (Fig 3E and
Appendix S4E), indicating that COMBO increased the expression of
Toll-like receptors, cytokines and their receptors (Il1b, Il18, Il6r),
interferon-related proteins (Irf2), monocytes/macrophage marker
(Cd14) and decreased the expression of many collagens. Last, we
performed a pathway analysis of the 258 genes that selectively char-
acterized the COMBO treatment, that is, the genes modulated by
COMBO versus vehicle. Ingenuity pathways analysis (IPA) revealed
gene networks similar to those previously predicted by GO enrich-
ment analysis. In particular, a 24-gene network related to collagen
deposition and a 26-gene network clustering around immune cell
trafficking displayed extensive regulation (Appendix Fig S4F). Taken
together, these results indicate that the combination of PLX4720
with bevacizumab specifically alters alternative biological pathways
associated with ECM remodeling, inflammation, and immune
response. Interestingly, IPA analyses revealed a network of cytokine
and chemokine genes that were also identified in the human tran-
scriptome. TNFa, TGFb, and IL1b were among the top five IPA
upstream regulators that were selectively modulated after COMBO
treatment (Appendix Table S5).
Dual BRAFV600E and VEGF targeting promotes macrophage
infiltration with a M1-like phenotype
The evaluation of angiogenic response to COMBO treatment
together with the gene expression analysis suggested that vascular
changes alone were unlikely to explain the enhancement of tumor
inhibition observed after COMBO regimen. Therefore, we investi-
gated whether the immune gene signature promoted by this treat-
ment resulted in recruitment of myeloid cells, which are still present
in CD1 athymic mice. Immunofluorescence staining for the pan-
hematopoietic cell surface marker CD45 revealed that only COMBO
treatment induced marked leukocyte infiltration in A375 xenografts
(CD45+ % area, 24.4  3.1%), which was negligible in vehicle-
treated mice (3.0  0.5%) or after treatment with PLX4720
(5.1  0.9%) or bevacizumab (6.9  1.4%) (n = 5 tumors; Fig 4A)
alone. A similar pattern was seen in COLO205 xenografts. Leukocyte
infiltration increased twofold after COMBO treatment (CD45+ %
area, COMBO: 9.3  1.2%; vehicle 3.8  0.5%), decreased after
PLX4720 treatment (2.3  0.3%), and increased modestly but not
significantly after bevacizumab treatment (4.9  1.1%) (n = 5
tumors; Fig 4A). The features of the infiltrate were further investi-
gated by specific immune phenotype analysis. We observed that
F4/80+ (Fig 4B) macrophages represented the most abundant
leukocyte population when the BRAFV600E and VEGF pathways were
simultaneously blocked in both A375 (F4/80+ area, 27.8  3.3%
vs. 8.4  1.2% in vehicle) and COLO205 (F4/80+ area,
10.6  1.5% vs. 2.7  0.8% in vehicle) xenografts. In both models,
the single-drug treatments did not modify the amount of infiltrating
F4/80+ cells compared with controls. Immunofluorescence results
were further confirmed by flow cytometry analysis (FACS) on
untreated and COMBO-treated A375 tumors. Fig 4C shows that
COMBO treatment induced a higher CD45+ leukocyte recruitment
compared with vehicle, which was mainly constituted by F4/80+
tumor-associated macrophages (TAMs) and CD11c+MHCII+
dendritic cells (DC) (Fig 4D).
To characterize the phenotype associated with the recruited
macrophages, we performed species-specific real-time quantitative
real-time PCR analysis to assess specific mouse transcripts relative
to the M1 and M2 polarization, which, respectively, have antitumor
and pro-tumor effects (Mantovani & Sica, 2009). Tumors treated
with COMBO expressed significantly higher amounts of M1 markers,
such as m-Ccl5, m-Cd40, m-Cxcl10, m-Cxcl9, m-Il1b, m-Stat1, and
m-Il1b, compared with vehicle-treated tumors. COMBO-treated
tumors also expressed reduced levels of the M2 marker m-Arg1
(Fig 5A), while m-Il10, which characterizes M2 polarization, was
not affected. Tumors treated with PLX4720 or bevacizumab alone
did not exhibit any significant modulation of macrophage-associated
genes (Fig 5A). The ability of COMBO treatment to induce a specific
TAM polarization was additionally analyzed by immunofluores-
cence analysis. Fig 5B shows that COMBO treatment specifically
increased the recruitment of CCR7+CD68+ M1 cells without any
effect on CD206+CD68+ M2 cells. These data were further
confirmed by ex vivo experiments on tumor cells isolated from
vehicle- and COMBO-treated xenografts and in vitro stimulated
with ionomycin and phorbol myristate acetate (PMA). Fig 5C
shows that COMBO regimen primed CD45+F480+ cells to
express more iNOS and TNFa, which characterize M1-polarization
(Mantovani & Sica, 2009), than vehicle. These observations suggest
that TAMs recruited by COMBO have an M1 phenotype, which can
explain the superior effect of the dual therapeutic regimen on tumor
burden compared with the effect of mono-therapies (Fig 1).
To discriminate between a systemic or tumor site-specific effect
of COMBO, we separately assessed the rate of circulating and tumor-
recruited inflammatory monocytes (CD45+Cd11b+Ly6Chigh cells;
Shi & Pamer, 2011). COMBO increased this cell population
in A375 tumors but not in bloodstream (Fig 5D and E).
CD45+CD11b+/Ly6Chigh tumor-resident monocytes were further
studied by the expression of inflammatory markers TNFa and iNOS
(Shi & Pamer, 2011) after in vitro stimulation with ionomycin and
PMA. As shown in Fig 5D, COMBO regimen enhanced the
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Figure 4. COMBO treatment increases macrophage infiltration.
A Representative images of leukocytes infiltration determined by immunofluorescence CD45 staining of A375 xenografts treated as indicated. Bar graphs indicate the
CD45+ area/tumor area in A375 and COLO205 xenografts (n = 5 tumors). ***P < 0.001 versus vehicle (A375: COMBO P = 2.19E-20) (COLO205: COMBO P = 1.81E-06).
B Representative images of macrophage infiltration determined by F4/80 immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate the
F4/80+ area/tumor area in A375 and COLO205 xenografts (n = 5 tumors). ***P < 0.001 versus vehicle (A375: COMBO P = 3.42E-13) (COLO205: COMBO P = 1.94E-06).
C A375 xenograft tumors after 14 days of treatment were subjected to FACS and tumor infiltrate was analyzed. Gating strategy for CD45+ cells and graph showing the
quantification of FACS analysis of infiltrating CD45+ leukocytes in vehicle (n = 4 tumors)- compared to COMBO (n = 6 tumors)-treated tumors. **P = 0.0064 versus
vehicle.
D Graph showing the quantification of FACS analysis of infiltrating F4/80+ macrophages and CD11c+MHCII+ dendritic cells in vehicle (n = 4 tumors)- compared to
COMBO (n = 6 tumors)-treated tumors. **P < 0.01 versus vehicle (TAM P = 0.0061; DC P = 0.0091).
Data information: The scale bars represent 100 lm in (A, B). The results are given as the mean  SEM. Significance was assessed by one-way ANOVA test followed by
post hoc pairwise analysis test (A, B) and Student’s t-test (C, D).
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expression of both markers as compared to untreated tumors. Inter-
estingly, when we analyzed the expression of macrophage chemotac-
tic cytokines produced by tumor cells in the xenograft model, we
observed a significant increase in human GM-CSF and human TNFa
levels after PLX4720 exposure independently from bevacizumab
treatment (Appendix Fig S5A). To determine whether this M1-like
phenotype correlated with enhanced antitumor effect, we co-
cultured the whole cell population isolated from vehicle- or COMBO-
treated xenografts with parental Zs-Green-A375 tumor cells to evalu-
ate the cytotoxic effect of leukocytes present in the tumors. Isolated
cells from COMBO-treated tumors induced higher cytolytic activity
of co-cultured Zs-Green-A375 cells than cells isolated from vehicle
tumors (Fig 5F). This result suggests that TAMs recruited by the
COMBO regimen display tumoricidal activity, most likely mediated
by the M1 phenotype.
COMBO also recruited neuropilin-1 expressing monocytes
(NEMs), a novel minute myeloid population with antitumoral and
vascular-normalizing effects (Carrer et al, 2012). We observed an
increase in the CD11b+Nrp1+Gr1 cells in dual therapy-treated
A375 xenografts compared with the controls (NEMs percentage
area, 5.2  0.9% vs. 1.4  0.3). Interestingly, PLX4720 alone was
ineffective, and bevacizumab showed an inhibitory trend of the
basal recruitment rate observed in absence of therapy (PLX4720,
2.2  0.8%, bevacizumab, 0.3  0.2%) (n = 5 tumors;
Appendix Fig S5B).
The amount of CD11b+Gr1+ cells, which identify myeloid-
derived suppressor cells (Shojaei et al, 2007), was negligible in
untreated tumors and in all treatment conditions (not shown).
Dual BRAFV600E and VEGF targeting promotes ECM remodeling
The microarray data also highlighted ECM remodeling in A375
xenografts. We therefore examined whether matrix deposition was
also affected by BRAFV600E and VEGF blockade. We observed
that COMBO treatment reduced the amount of type I collagen area
fraction (COMBO: 7.3  0.9% vs. vehicle: 14.9  1.1%), while
neither single agent was effective (type I collagen-positive
area, PLX4720 14.6  1.3%; bevacizumab: 16.7  0.9%) (n = 5
tumors; Fig 6A). The significant reduction in collagen I in
COMBO-treated tumors indicates that blockade of BRAFV600E and
VEGF induces the degradation of matrix or prevented matrix
production. In tumors, ECM dynamics are largely orchestrated by
cancer-associated fibroblasts (CAFs) (Kalluri & Zeisberg, 2006).
Therefore, we investigated whether COMBO treatment could
also reduce CAF density. Tumor sections were stained with an
antibody against aSMA, a specific marker of CAF and pericytes.
We observed that COMBO treatment lowered the density of
non-perivascular aSMA-positive cells, suggesting a decrease in
CAFs (n = 5 tumors; Fig 6B).
Of relevance, microarray analyses of murine gene expression
data indicated that proteolytic enzymes, including matrix metallo-
proteinases (Mmp3, Mmp9, Mmp10; Fig 3E) were reduced after
COMBO treatment. Therefore, it is plausible that the reduced
amount of collagen I in COMBO-treated tumors mainly reflects
impaired deposition rather than increased degradation. We investi-
gated also the expression of lysyl oxidase (LOX), which regulates
tissue stiffness by collagen cross-linking (Barker et al, 2012). Of
interest, COMBO treatment reduced the LOX expression (COMBO:
3.5  0.7% vs. vehicle: 6.6  0.8%), while PLX4720 single-drug
treatment did not alter its expression and bevacizumab modestly
increased its levels (n = 3 tumors; Fig 6C). Accordingly, IPA analy-
ses of murine gene modulated by COMBO indicated that TGFb1
signaling, which is involved in regulating the cellular production of
ECM molecules and CAF differentiation (Shukla et al, 2014), was a
top upstream regulator of the class of genes negatively modulated
by COMBO (Fig 6D and Appendix Table S5). The value of this
computational prediction was experimentally confirmed. COMBO
did not significantly modify the abundance of murine Tgfb1 mRNA,
but it was the most effective treatment in reducing the level of
human TGFb analyzed by a pan TGFb antibody and of human
TGFB1 transcript (Fig 6E and F).
TAMs recruited by COMBO regimen are instrumental in the
enhanced antitumor effect
To explore the role of TAMs in the enhanced tumor activity
observed in COMBO treatment, clodronate liposomes were used to
deplete macrophages during treatments. Clodronate alone promoted
a tumor inhibitory effect as previously reported in other tumor
models (Fischer et al, 2007). Nevertheless, clodronate co-adminis-
tration impaired the effect of COMBO, which had a cytostatic effect
without inducing tumor shrinkage (COMBO plus clodronate:
Figure 5. Macrophages infiltrated after COMBO treatment are polarized toward M1-like phenotype.
A Real-time quantitative PCR of the indicated genes (M1-like and M2-like macrophages markers) in A375 xenograft treated with PLX4720, bevacizumab, or COMBO.
Data are presented as expression fold change (log2) compared with vehicle after normalization for housekeeping gene TBP (n = 3 tumors). *P < 0.05, **P < 0.01,
***P < 0.001 versus vehicle (PLX4720: m-Arg1 P = 5.65E-06) (bevacizumab: m-Ccl5 P = 0.025) (COMBO: m-Ccl5 P = 0.0070; m-Cd40 P = 0.00099; m-Cxcl10
P = 0.043; m-Cxcl9 P = 0.046; m-Il1b P = 0.0367; m-Stat1 P = 0.049; m-Tlr2 = 0.00182; m-Arg-1 P = 0.0013).
B Representative images of COMBO-treated tumor sections co-stained with an antibody against CD68 and an anti-CCR7 antibody (M1-like polarization) or anti-C206
antibody (M2-like polarization). The scale bars represent 50 lm.
C Graphs showing the quantification of FACS analysis of infiltrating F4/80+ tumor macrophages and average percentage of median fluorescence intensity (MFI) of
TNFa+ or INOS+ on F4/80+ cells after ex vivo stimulation with PMA and ionomycin in vehicle (n = 4 tumors) and COMBO (n = 6 tumors), *P < 0.05 versus vehicle
(TNFa P = 0.037; INOS P = 0.038).
D Graphs showing the quantification of FACS analysis of infiltrating CD11+Ly6C+ tumor monocytes and average percentage of MFI of TNFa+ or INOS+ on CD11+Ly6C+
cells after ex vivo stimulation with PMA and ionomycin in vehicle (n = 4 tumors) and COMBO (n = 6 tumors), *P < 0.05 versus vehicle (TNFa P = 0.048; INOS
P = 0.038).
E Graph showing the quantification of circulating CD11+Ly6C+ monocytes in peripheral blood analyzed by FACS in vehicle (n = 4 tumors)- and COMBO (n = 6 tumors)-
treated tumors.
F Cell viability measured as fluorescence intensity of ZsGreen-A375 cells co-cultured with cells isolated from xenograft treated with vehicle or COMBO after 48 h. Data
are representative of one experiment of two done in triplicate. *P = 0.046 versus vehicle.
Data information: The results are given as the mean  SEM. Significance was assessed by Student’s t-test (A–F).
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129.6  35.2% of tumor starting size, COMBO: 33.2  14.6% of
tumor starting size; Fig 7A). Immunofluorescence staining of
F4/80+ cells confirmed that clodronate liposomes really depleted
macrophages in COMBO-treated A375 tumors (F4/80+ area,
23.5  1.7% in COMBO group and 2.2  0.2% in COMBO clodro-
nate group; Fig 7B). Interestingly, the decreased type I collagen
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deposition induced by COMBO treatment still persisted in the pres-
ence of clodronate liposomes (Fig 7C), suggesting that the ECM
remodeling mostly depended on a direct effect of the combination of
VEGF and BRAF inhibition.
COMBO regimen delays the onset of acquired resistance to
BRAFV600 inhibition by PLX4720
Clinical experience with the PLX4720 analog vemurafenib recently
demonstrated that the efficacy of long-term treatment for patients
with melanoma is hampered by the inevitable development of
acquired resistance to the drug (Bollag et al, 2010; Flaherty et al,
2012). Therefore, we investigated the therapeutic effect of PLX4720
and bevacizumab alone or in combination over a period of 6 weeks
in melanoma A375 xenografts. After 2 weeks of treatment, detect-
able tumor relapse progressively occurred in mice that received
mono-therapy with PLX4720 or bevacizumab. After 6 weeks, tumor
volumes were comparable to untreated controls (Appendix Fig
S6A). In COMBO-treated mice, only three of six tumors resumed
growth after 6 weeks while three were still in response (one
complete, two partial; Fig 7D).
Interestingly, infiltrating F4/80+ macrophages were still
massively detectable in the responding mice but almost absent
from relapsed ones (F4/80+ area, 29.8  3.4% in responder
mice and 6.7  0.8% in relapsed mice; Fig 7E). In accordance,
relapsing mice showed an increase in type I collagen area (colla-
gen I+ area, 13.6  1.6% in responder mice and 21.6  1.1% in
relapsed mice; Fig 7F). Of note, the transcript of pro-fibrotic
cytokine TGFb1 (Shukla et al, 2014) was increased in tumor
cells of relapsing mice (Fig 7G). We also confirmed the M1
phenotype of macrophages recruited in responder mice
(Appendix Fig S6B). The level of transcripts encoding GM-CSF,
which activates and primes leukocytes, was also higher in
responder than in relapsing tumors (n = 3 tumors; Appendix Fig
S6C). Furthermore, as indicated by CD31 staining, relapsing
tumors still exhibited MVA reduction (Appendix Fig S6D), which
was accompanied by an increase in hypoxic area (n = 3 tumors;
Appendix Fig S6E).
Collectively, these results indicate that M1-like macrophages
recruited by COMBO prolonged remission in mouse xenografts and
effectively helped to delay the onset of acquired resistance to
PLX4720.
Discussion
The connections between cancer and stroma cells are a largely
unexplored area of cancer biology. These connections can deeply
▸
Figure 6. COMBO treatment reduces collagen deposition in A375 xenografts.
A Representative images of collagen deposition determined by collagen I immunofluorescent staining in A375 xenografts treated as indicated. Bar graphs indicate the
collagen I+ area/tumor area (n = 5 tumors). ***P = 2.93E-06 versus vehicle.
B Representative images of CAF density determined by a-SMA immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate a-SMA+
area/tumor area (n = 5 tumors). ***P = 0.0006 versus vehicle.
C Representative images of lysyl oxidase enzyme determined by LOX immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate the LOX+
area/tumor area (n = 3 tumors). *P < 0.05 versus vehicle (bevacizumab P = 0.033; COMBO P = 0.040).
D Ingenuity pathway analysis (IPA) identified TGFb1 as one of the most significant upstream regulators (activation z-score = 4.753, P = 2.1E10E-29; predicted
activation state: inhibited) of the specifically modulated genes after COMBO treatment, according to microarray analysis. Shades of red indicate the degree of up-
regulation while shades of green indicate the degree of down-regulation of significant downstream genes.
E Quantitative real-time PCR of h-TGFB1 and m-Tgfb1 of A375 xenograft treated with PLX4720, bevacizumab, or COMBO. Data are presented as expression fold change
(log2) compared with vehicle after normalization for the housekeeping gene TBP (n = 3 tumors). *P = 0.043 versus vehicle.
F Western blot for human TGFb in total protein extract from A375 tumors treated as indicated. Vinculin was used as an internal control.
Data information: The scale bars represent 100 lm in (A–C). The results are given as the mean  SEM. Significance was assessed by one-way ANOVA test followed by
post hoc pairwise analysis test (A–C) and Student’s t-test (E).
Source data are available online for this figure.
Figure 7. Bevacizumab delays tumor relapse after acquired resistance to PLX4720 in A375 xenografts through macrophage recruitment.
A Effect of clodronate liposomes on tumor growth inhibition induced by COMBO treatment in mice bearing A375 tumors. Tumor growth is expressed as % change of
the initial tumor. Macrophage depletion by clodronate liposome enhanced the tumor growth of tumors treated with the combination of PLX4720 and bevacizumab
(n = 5 mice/group). *P = 0.049 vehicle + clodronate versus vehicle, ***P = 5.72E-06 COMBO versus vehicle, ŦP = 0.033 COMBO + clodronate versus COMBO.
B Representative images of macrophage infiltration determined by F4/80 immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate the
F4/80+ area/tumor (n = 3 tumors), ***P = 1.53E-25 versus vehicle.
C Representative images of collagen deposition determined by collagen I immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate the
collagen I+ area/tumor (n = 3 tumors).
D Waterfall plots showing the percent change in volume (relative to the initial tumor volume) for the individual A375 xenografts in each treatment group (vehicle,
PLX4720, bevacizumab, and COMBO) from week 1 to week 6.
E Representative images of macrophage infiltration determined by F4/80 immunofluorescence staining in a responder and a relapsing A375 xenografts. Bar graphs
indicate the F4/80+ area/tumor (n = 3 mice). ***P = 1.25E-06 versus vehicle.
F Representative images of collagen deposition determined by collagen I immunofluorescence staining in a responder and a relapsing A375 xenografts. Bar graphs
indicate the collagen I+ area/tumor (n = 3 mice). ***P = 4.03E-05 versus vehicle.
G Real-time quantitative PCR of h-TGFB1 in A375 xenograft treated with PLX4720, bevacizumab, or COMBO. Data are presented as expression fold change (log2) of
relapsing tumors compared to responder tumors after normalization for the housekeeping gene TBP (n = 3 tumors). ***P = 0.0006 versus vehicle.
Data information: The scale bars represent 100 lm. The results are given as the mean  SEM. Significance was assessed by one-way ANOVA test followed by post hoc
pairwise analysis test (A) and Student’s t-test (B, C, E–G).
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influence not only cancer progression but also the clinical
responses to oncogene-targeted therapies (Mantovani & Allavena,
2015).
Here, we demonstrate that targeting the vascular compartment of
tumor tissue with bevacizumab can modulate response to PLX4720
of melanoma xenografts harboring the BRAFV600E mutation. The
A
D
B
E
G
C
F
Figure 7.
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final result of the drug combination is an enhanced anticancer effect
and a delay of the onset of resistance to PLX4720. This effect is the
result of the following biological processes, which are not triggered
by treatment with either drug alone: (i) the recruitment of M1 polar-
ized TAMs, which have efficient antitumor activity (Mantovani &
Sica, 2009); and (ii) remodeling of the ECM characterized by a
reduction in collagen I and in CAFs. This cooperative effect is medi-
ated by the adoption of a de novo transcriptional signature (neomor-
phic effect) (Pritchard et al, 2013), that was not observed in the
presence of either agent alone.
The COMBO treatment triggers a neomorphic footprint mainly
characterized by the presence of M1-like TAMs. This immune
response is sustained by a general modification of the entire tumor
transcriptional landscape characterized by an enrichment of genes
related to leukocyte recruitment. We hypothesize that the COMBO
promotes the recruitment of inflammatory monocytes that undergo
M1 polarization switch necessary for the enhanced efficacy of this
regimen on A375 xenografts compared to single agents. This
hypothesis is based on the in vitro cytotoxic effect on A375 cells of
the bulk tumor cell population isolated from COMBO-treated mice,
but not from untreated mice had. Furthermore, the comparative
analysis of responder and relapsing A375 xenografts after long-
term COMBO treatment demonstrated that M1-like TAM infiltrate
persists in the former but not in the latter. Interestingly, BRAFV600E
inhibition by PLX4720 can dampen the immune-suppressive activ-
ity observed in melanomas (Khalili et al, 2012; Frederick et al,
2013).
A second effect of COMBO treatment on myeloid compartment is
an increase in a subpopulation expressing neuropilin-1 and CD11b,
which have been reported to favor vascular normalization and
inhibit tumor growth when directly injected in B16.F10 melanomas
at relative high cell concentration (2 × 105 cells/tumor) (Carrer
et al, 2012).
The second neomorphic effect of COMBO influences genes
involved in ECM remodeling and cell-matrix adhesion. Similar to
the signature reported by Hirata et al (2015), PLX4720 monotherapy
of A375 xenografts increased the transcription of human genes
involved in ECM organization and biological cell adhesion. The
administration of PLX4720 in combination with bevacizumab coun-
teracted this signature and reduced the number of CAFs and the
amount of collagen I. As reported for M1-like TAM infiltrate, respon-
der mice to the COMBO continue to show reduced amount of
collagen, but relapsing do not. These data confirm and extend the
relevance of ECM and CAFs in priming resistance to BRAFV600E inhi-
bition. Paradoxically, CAFs are activated by vemurafenib or its
analogue PLX4720 and they produce hepatocyte growth factor
(HGF), which re-activates the MAPK signaling pathway, resulting in
BRAF inhibition. This effect is reversed by blocking the HGF/MET
axis (Straussman et al, 2012; Wilson et al, 2012). A second mecha-
nism has been recently identified and demonstrates that the para-
doxical activation of fibroblastic stroma triggered by PLX4720
modifies tumor stiffness, which provides an alternative route of
MAPK activation by an integrin-mediated outside-in effect, resulting
in cancer survival (Hirata et al, 2015).
COMBO does not increase the expression of ECM degrading
MMPs, but it reduces the expression of LOX, a key enzyme in the
formation of collagen fibrils (Barker et al, 2012), supporting the
notion that VEGF removal by bevacizumab can balance the effect of
PLX4720 on ECM and its negative consequence on therapeutic
response.
However, other mechanisms could explain the effect of COMBO
treatment on the fibroblast compartment. Interestingly, vascular
normalization induced by the calcium antagonist verapamil with
cilengitide, an integrin mimetic peptide, reduces ECM deposition
and the desmoplastic reaction in a model of pancreatic ductal
adenocarcinoma (Wong et al, 2015).
The effect of COMBO on ECM deposition can also affect the
inflammatory response. For example, mice lacking the ECM glyco-
protein SPARC have an increased number of macrophages in
tumors (Puolakkainen et al, 2004). Additionally, collagen I has
inhibitory effects on immune cells, attenuating their tumor-
suppressive function. Collagen inhibits the ability of macrophages
to kill cancer cells by blocking their polarization and activation
(Kaplan, 1983). Collagen deposition in tumor microenvironment
has also been directly implicated as a barrier to T-cell entry and
subsequent cytotoxic activity (Salmon et al, 2012). Finally, LOX
inhibition in transgenic mice developing pancreatic adenocarci-
noma prolongs tumor-free survival and is associated with
decreased fibrillar collagen and increased infiltration of macro-
phages and neutrophils (Miller et al, 2015). In general, strategies
alleviating the forces that cause vessel compression improve
perfusion and subsequent cell trafficking and delivery of drugs
(Stylianopoulos & Jain, 2013).
The third neomorphic effect of COMBO concerns the ability of
PLX4720 to modulate the effect of bevacizumab on blood vessels.
Bevacizumab and, in general, all drugs targeting the VEGF/VEGF
receptors axis reduce tumor capillaries by abrogating the pro-
survival and proliferative effects of VEGF (Ferrara et al, 2003). In
principle, drastic shrinkage of tumor vasculature promotes hypoxia,
which can favor tumor progression in preclinical models (Ebos et al,
2009; Paez-Ribes et al, 2009). Based on our previous observations
(Bottos et al, 2012), PLX4720 normalizes the tumor vasculature
with a reduction in hypoxic areas and improves blood flow. These
effects also persist in the presence of bevacizumab, which alone
does not improve basal perfusion and tumor oxygenation. In accor-
dance with these functional observations, PLX4720 and COMBO
treatments result in decreased expression of genes regulating angio-
genesis and the response to hypoxia.
The vascular-normalizing effect of COMBO could function coop-
eratively with the above neomorphic effect on macrophage recruit-
ment and indirectly favor the adaptive immune response. This
hypothesis is supported by the evidences accumulated in responder
and relapsing mice characterized by the correlation between the
normoxic state and the abundance of TAMs. Substantial evidences
suggest that the rescue of the hypoxic state by vascular perfusion
reprograms the tumor microenvironment from immunosuppressive
to immunosupportive. Vascular normalization facilitates the infiltra-
tion of cytotoxic T cells (Huang et al, 2012), and M2 and M1 polar-
izations are, respectively, promoted by hypoxia and normoxia
(Casazza et al, 2013; Laoui et al, 2014). Hypoxia also recruits regu-
latory T-cell (Treg) effectors for tumor tolerance (Facciabene et al,
2011), and up-regulates the expression of programmed death (PD-1)
ligand 1 (Noman et al, 2014), which favors the suppressive activity
of MDSC (Greenwald et al, 2005). Among the immunosuppressive
factors produced by tumor cells, VEGF plays a key role in suppress-
ing dendritic cell maturation (Gabrilovich et al, 1996), thus
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impairing an effective tumor antigens presentation and the rise of
specific antitumor immunity. VEGF promotes MDSC differentiation
(Lechner et al, 2010) and regulatory T-cell proliferation (Terme
et al, 2013). Then, FLT-1 expressing monocytes can be recruited by
VEGF into the tumor (Mantovani & Sica, 2009) and act together with
the Th2 cytokine IL-4 to promote M2 polarization of macrophages
(Linde et al, 2012). The immune-suppressive role of VEGF was
further highlighted by the delayed melanoma growth observed after
its silencing. VEGF down-modulation resulted in a decrease in Tregs
and MDSC and an increased effector T-cell activation in tumor infil-
trates. Together, these events restored tumor sensitivity to treatment
with antibodies against the checkpoint inhibitors PD-1 and CTLA-4
(Courau et al, 2016).
Our findings provide an intriguing experimental platform to
explore possible synergism with immunotherapy strategies and
support a previous study performed in mice transplanted with a
BRAFV600E melanoma cell line poorly sensitive to PLX4720 (Knight
et al, 2013). In this model, the BRAF inhibitor did not increase the
tumor immunogenicity, but it favored the recruitment of CD8 and
natural killer cells. PLX4720 treatment significantly reduces the
production of tumoral VEGF, enhancing tumor infiltration by anti-
gen-specific T lymphocytes (Liu et al, 2013). In general, contrasting
the VEGF effect along with simultaneous BRAF inhibition can turn
into a promotion of adaptive immune responses. From a clinical
perspective of the treatment of BRAF-mutated melanomas, this
synergism could be exploited with either immune-checkpoint modu-
lators (Anti-PD1 Ab or Anti CTLA-4) (Postow et al, 2015) or with
approaches based on adoptively transferred antitumor lymphocytes
(Kwong et al, 2013). Antitumor T cells avoid hypoxic areas, and
tissue oxygenation restores their activity and efficacy of checkpoint
inhibitors (Hatfield et al, 2015). Interestingly, bevacizumab shows
synergistic effect with ipilimumab, which blocks CTLA4, improving
survival in patients with metastatic melanoma (Hodi et al, 2014).
Therefore, our findings provide biologic strong rational to explore,
within dedicated immunocompetent models, the potential beneficial
modulation of antitumor adaptive immune response consequent to
the double VEGF and BRAF inhibition.
Our holistic experimental approach is poorly instructive on the
molecular players involved by COMBO and on the cellular targets.
However, bioinformatic predictions experimentally validated (Fig 6)
suggest that human TGFb1 is one of the strong candidate to orches-
trate the neomorphic effects of COMBO in A375 xenografts. Actu-
ally, the pleiotrophic roles of TGFb1 include the suppressive activity
(Yang et al, 2010), the capability to promote CAF differentiation and
ECM remodeling (Evans et al, 2003; Shukla et al, 2014), and the
vascular regulatory functions (Jakobsson & van Meeteren, 2013).
On the basis of the differential transcriptomic effects of beva-
cizumab and PLX4720 alone, we can predict that bevacizumab has
an exclusive effect on stroma. However, PLX4720 has a wider effect
on both tumor and stromal cells, as also reported by the literature
(Straussman et al, 2012, Wilson et al, 2012; Hirata et al, 2015).
Overall, our data suggest that in preclinical models the removal
of VEGF can increase the efficacy of BRAFV600E inhibitors by induc-
ing vascular normalization, overcoming immune tolerance and
modifying the role played by CAFs. Further experiments will be
required to investigate how T and B cells, which are absent in CD1
mice used in this work, modify the functional performance of the
association between BRAFV600E targeting and VEGF removal.
Materials and Methods
Cell lines and reagents
MC-1 cells were kindly provided by L. Xu and R.O. Hynes (Mas-
sachusetts Institute of Technology, Boston) and maintained in
DMEM containing GlutamaxTM (GIBCO Invitrogen Life Technologies,
Carlsbad, CA, USA) and supplemented with 10% fetal bovine serum
(FBS), 1 mM sodium pyruvate, 25 mM HEPES pH 7.4, 1 × MEM
vitamin solution, 1 × MEM non-essential amino acids and
100 lg/ml gentamicin (all from Invitrogen Life Technologies). A375
and COLO205 were obtained from ATCC. A375 and COLO205 were,
respectively, maintained in DMEM and in RPMI1640 with 10% FBS.
All media were supplemented with 1% penicillin/streptomycin and
2 mM glutamine. The cells were grown according to standard proto-
cols in a 37°C humidified, 5% CO2 incubator. All cell lines were
regularly verified as mycoplasma-free using a PCR-based test (Min-
erva Biolabs). Cell lines were authenticated by short tandem repeat
profiling (Cell ID System; Promega) at 10 different loci (D5S818,
D13S317, D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO,
and amelogenin).
PLX4720 was purchased from Selleck Chemicals, dissolved in
DMSO at a final concentration of 500 mM and stored in aliquots at
80°C. Clinical-grade bevacizumab (Avastin, Roche) was stored as
a stock solution of 25 mg/ml.
Immunofluorescence analyses
Tumors samples were frozen in OCT compound and cut into 10-lm-
thick sections after overnight treatment at 4°C in 30% sucrose solu-
tion. Tissue slices were fixed in 4% paraformaldehyde for 10 min
at room temperature. The antibodies used for specific human
or murine tissue immunostaining were as follows: anti-Ki67
(#MA5-14520; Invitrogen); anti-CD31 (#550274; BD Pharmingen);
anti-NG2 (#AB5320; Millipore); anti-CD45 Alexa Fluor 647-conjugated
(#103124; Biolegend); anti-CD68 (#ab125212; Abcam); anti-F4/80
(#MCA497A488; Bio-Rad); anti-collagen I (#ab21286; Abcam);
anti-LOX (#ab31238; Abcam); anti-a-SMA Cy3-conjugated (#C6198;
Sigma); anti-Gr1 (#108402; BioLegend); anti-Nrp1 (#AF566; R&D
Systems); anti-CCR7 (#NB100-712; Novusbio); anti-CD206 Alexa
Fluor 488-conjugated (#141710; Biolegend); and anti-CD11b PE-
conjugated (#12-0112-82; Affymetrix eBioscience). The sections
were then incubated with the appropriate fluorescence-conjugated
secondary antibodies (Alexa 647 or 488, Life Technologies), and
nuclei were counterstained with DAPI (Life Technologies). The
samples were mounted using fluorescent mounting medium (Dako).
All immunofluorescence images were captured and analyzed using
a Leica SPEII confocal laser-scanning microscope (Leica Microsys-
tems). Image acquisition was performed maintaining the same laser
power, gain, and offset settings. Multiple independent fields (15–20
for every sections; 20× or 40× magnification) per tumor section were
randomly chosen and analyzed from at least three tumors for each
experimental condition. Image quantification was performed using
NIH ImageJ and expressed as the fluorescence area. The MVD and
MVA were quantified by counting CD31+ vessels per mm2 and
measuring the CD31+ area in the total field area. CD31+ vessels
were hand traced using ImageJ image analysis software to calculate
the lumen vessel perimeter and area. Perivascular pericyte coverage
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was quantified by double staining of CD31 and NG2. Cell apoptosis
was assessed by terminal deoxynucleotidyl transferase dUTP nick-
end labeling (TUNEL) assay (Roche) according to the manufac-
turer’s specifications and by M30 CytoDEATH antibody (Roche),
which recognizes a cytokeratin 18-specific cleavage product of the
caspase cascade. All figures are representative of a tumor with a size
included the in median size of the group analyzed.
Tumor hypoxia and perfusion
Tumor hypoxia was detected by the formation of pimonidazole
adducts at 1 h after intraperitoneal (i.p.) injection of 60 mg/kg
pimonidazole hydrochloride in tumor-bearing mice. Mice were then
sacrificed, and the tumors were harvested. Frozen sections were
immunostained with hypoxyprobe-1-FITC-conjugated antibody
(#MAb1; Hypoxyprobe Inc), according to the manufacturer’s
instructions. To visualize the functional blood vasculature, 200 ll of
orange fluorescent microspheres (FluoSpheres; Life Technologies)
was administered intravenously 10 min before tumor excision. The
tumors were then frozen in OCT for immunofluorescence analysis
and stained for CD31. The microsphere distribution was visualized
by confocal microscopy using 10-lm sections, and tumor perfusion
was analyzed by counting the % of double-positive blood vessels.
Ten sections were analyzed per tumor.
In vivo tumor growth and lung colonization assays
A375 (107) or COLO205 (5 × 106) cells were subcutaneously
injected in 6-week-old CD1 female athymic mice (Charles River).
Tumor size was measured with a caliper, and tumor volume was
calculated by the modified ellipsoid formula: length × (width)2/2.
When tumors reached a volume of approximately 250–300 mm3,
mice were randomly assigned to different treatment groups, which
were maintained for 2 or 6 weeks. During randomization, mice with
a tumor size lower or higher than 250–300 mm3 were excluded.
For lung colonization assay, 5 × 105 MC-1 cells were injected
into the tail vein of 6-week-old CD1 female mice and the animals
mice were randomly assigned to different groups 12 weeks later.
Micrometastases were blindly evaluated by light microscopy on
paraffin-embedded and HE-stained slides. Five sections per tumor
were analyzed.
Mice were treated with PLX4720 (daily oral gavage at 60 mg/kg,
dissolved in a vehicle of 1% w/v methylcellulose in sterile water),
bevacizumab (3 times a week by i.p. administration at 10 mg/kg,
diluted with sterile 0.9% saline), the combination of PLX4720 and
bevacizumab (COMBO), or equivalent volumes of vehicles.
To identify all significant therapeutic responses with a statistical
power of 95%, we calculated the mice sample size by considering:
(i) volume variations of  40% as random; (ii) volume variation of
at least 50% as a therapeutic effect; (iii) a statistical significance of
P = 0.05. Accordingly, at least five mice/group were used. Animal
procedures were approved by the ethical committee of the Univer-
sity of Turin and by the Italian Ministry of Health.
Microarray experiments
For gene expression profiling analysis, 300 ng of total RNA was
amplified and labeled using an Illumina TotalPrep RNA
Amplification Kit (Life Technologies). A total of 750 ng of 1,500 ng
of labeled cRNA probes was hybridized on the HumanHT-12 v4.0 or
MouseWG-6 v2.0 Expression Bead Chip, respectively (Illumina). All
experiments were performed in biological triplicate (duplicate for
COMBO group). Cubic spline-normalized probe intensity data,
together with detection P-values, were obtained using the Genome-
Studio software V2011.01 (Illumina). We selected probes character-
ized by at least one experimental point having a detection P-value
< 0.05. For each gene, we retained the associated probe with the
largest mean expression value across all samples. The data were
log2 transformed for all subsequent analyses. For each probe, the
log2 signal in each sample was converted to the log2 ratio against
the global average expression of that probe in all samples. The log2
ratio expression data were clustered and visualized using GEDAS
software (Fu & Medico, 2007). One-way ANOVA test and LIMMA
(Smyth, 2005) were used to identify the modulated genes. For the
ANOVA test, P-values were corrected for multiple testing using a
Benjamini–Hochberg procedure (Benjamini & Hochberg, 1995), and
a cutoff of 0.1 for the false-discovery rate (FDR) was used to define
differentially modulated genes across all four experimental
conditions. In the LIMMA analysis, a threshold of | log2 FC | of 1 and
P-value < 0.01 were used to select genes modulated to the greatest
extent; each of the treatments was compared separately to the
control samples. The data were analyzed for enrichment in biologi-
cal themes (GO—Biological Processes) using the Database for Anno-
tation, Visualization, and Integrated Discovery Bioinformatics
Resources (DAVID, https://david.ncifcrf.gov).
Gene set enrichment analysis was performed according to the
public application from the Broad Institute (http://www.broadinsti
tute.org/gsea/msigdb/download.jsp). In particular, after gene filter-
ing, for all the datasets, probes were collapsed on Gene Symbols,
again selecting for each Gene the probe with the largest mean
expression across all the experiments. GSEA Enrichment statistics
were performed with the default setting, based on Pearson metric.
P-values and FDRs were calculated by repeating sample permuta-
tions 1,000 times.
Ingenuity pathways analysis (Ingenuity Systems) was used to
generate gene networks of significantly regulated groups of genes
and identify related significant biological functions. Melanoma A375
xenograft microarray data have been deposited in The Gene Expres-
sion Omnibus of the National Center for Biotechnology Information
(accession number GSE69754).
Quantitative real-time PCR
Total RNA was extracted from tumors using an RNeasy mini kit
(Qiagen). For cDNA synthesis, a High-Capacity cDNA Reverse Tran-
scription kit (Life Technologies) was used according to the manufac-
turer’s instructions. An RNA quality check, including concentration
and purity, was performed with a Nanodrop ND-100 (Nanodrop
Technologies). Quantitative real-time PCR was performed on a
CFX96 (Bio-Rad) using SYBR-green PCR MasterMix (Life Technolo-
gies). The PCR thermal profiles were 95°C for 15 s and 60°C for 60 s
(40 cycles). All experiments were performed in duplicate. Melting
curve analysis was performed for each PCR to confirm the speci-
ficity of the amplifications. The housekeeping gene TBP was used to
normalize the expression data. The primer sequences and product
sizes are indicated in Appendix Table S6.
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Western blotting
Whole tumor samples were lysed in 1 ml of EB buffer (150 mM
NaCl, 5 mM EDTA pH 8, 10 mM Tris–HCl pH 7.5, 1 mM Na3VO4,
1 mM Phenylmethylsulfonyl fluoride, protease inhibitors cocktail,
10% Glycerol, 1% Triton X-100) and dissociated by gentleMACS
dissociator (Miltenyi Biotec). Samples were clarified by centrifuga-
tion for 10 min at 10,000 g, and proteins (30 lg) were resolved in a
4–20% SDS–PAGE gels and transferred onto PVDF membranes.
Blots were incubated overnight at 4°C with mouse anti-TGFb
(#ab66043; Abcam) or rabbit antivinculin (#V9131; Sigma) antibod-
ies (both at 1:1,000). After washing, membranes were incubated
with horseradish peroxidase-conjugated secondary antibodies
(1:10,000; Jackson). The immunoreactive bands were visualized by
enhanced chemiluminescence detection kit (Perkin-Elmer Life
Science Products) with the ChemidocTM Touch Imaging system (Bio-
Rad Laboratories, Inc). Band quantification was performed using
Bio-Rad Quantity One software.
Flow cytometry
Tumor lysates were prepared by mincing the tumor in DMEM
(Sigma) and incubating in collagenase (Roche) at 37°C for 1 h. After
washing in PBS, the cells were filtered through 70-lm filters (BD
Biosciences). 5 × 10 cells were re-suspended in HBSS (Hank’s
balanced salt solution, Lonza) supplemented with 0.5% BSA
(Sigma). Staining was performed at 4°C for 20 min, with the
following antibodies: anti-mouse CD45 (clone 30-F11, Biolegend
San Diego, CA, USA), anti-mouse F4/80 (clone BM8, Biolegend
San Diego, CA, USA), anti-mouse cd11c (clone N418, Biolegend San
Diego, CA), anti-mouse I-A/I-E (clone M5/114.15.2, Biolegend San
Diego, CA, USA); anti-mouse TNFa (clone MP6-XT22, BD Pharmin-
gen), anti-mouse Ly6C (clone HK1.4, eBioscience; San Diego, CA,
USA); anti-mouse NOS2 (clone 6/iNOS/NOS Type II, BD bio-
sciences, San Diego, CA, USA) and mouse IgG2a K (BD biosciences,
San Diego, CA, USA). For intracellular staining, Cytofix/Cytoperm
and Permwash staining kit (BD Pharmingen) were used. Cells were
detected using the BD FACS Canto II cytofluorimeter and analyzed
with FlowJo software.
Cell co-culture
To evaluate the in vitro cytotoxic effect of the tumor cell population
on A375 cells, the cells were infected with pLVX-ZsGreen1-N1 lenti-
virus (Clontech). Vector production was achieved in HEK-293T cells
transfected with pLVX-ZsGreen1-N1 and packaging plasmids. Selec-
tion was achieved by a 24-h cell incubation with puromycin
(2 lg/ml). Tumor cells (5 × 104) recovered as described in the
“Flow cytometry” section were co-cultured with Zs-green-A375 cells
(5 × 104) in 96-well plates (final volume, 70 ll). Fluorescence was
recorded at day 0 and days 2 by fluorescence microscopy (Leica
DMI3000B) and analyzed by NIH ImageJ software.
Macrophage depletion
Macrophage depletion was obtained by treating mice 1 week after
A375 cell implantation with i.p. injection of clodronate liposome
(200 ll) (Encapsula Nanosciences, Brentwood, TN, USA) and
repeated three times per week up to the end of COMBO
treatment.
Statistical analyses
The data are presented as the mean  SEM. Student’s t-test (two
tailed) or one-way ANOVA, followed by post hoc pairwise analysis
test, was performed using GraphPad Prism version 6.00 (GraphPad
Software, La Jolla, CA, USA, www.graphpad.com). P-value < 0.05
was considered significant. The stars in the graphs indicate signifi-
cance, as detailed in the figure legends.
Expanded View for this article is available online.
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The paper explained
Problem
In the last 20 years, cancer treatment is significantly improved by the
availability of drugs specifically targeting mutant oncogenes. However,
the success of target therapies is usually dampened by the appear-
ance of acquired resistance and disease relapse. More than half of
melanomas are characterized by an activating BRAF mutation and
transiently respond to BRAFV600E inhibitors, but almost all patients
develop resistance to these agents and subsequently relapse. There-
fore, there is a cogent clinical need to design new strategies to control
and delay the onset of resistance.
Results
The results of clinical trials using anti-angiogenic regimens to restrain
tumor progression have been somewhat disappointing. However, judi-
cious inhibition of VEGF promotes vascular normalization and favors
the delivery of small molecules to tumors. Therefore, a promising
application of anti-angiogenic drugs is their combination with other
therapeutic strategies. We tested a combination of bevacizumab and
the vemurafenib analog PLX4720, which target BRAFV600E, and
observed de novo transcriptional profile that sustains decrease of
tumor hypoxia, accumulation of antitumor macrophages, and reduc-
tion in cancer-associated fibroblasts. These unexpected effects delayed
the onset of resistance to PLX4720.
Impact
Our findings offer a new perspective for the management of clinical
resistance to BRAF inhibitors. Furthermore, the observation that the
association of BRAF inhibitors with bevacizumab elicits the recruit-
ment of antitumor macrophages supports the concept of combining
this strategy with immune-based therapies.
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